Meeder Advisory Services Inc. Raises Stock Position in Eli Lilly and Company $LLY

Key Points

• Meeder Advisory Services increased its Eli Lilly position by 4.6% in the second quarter, bringing its holdings to 20,367 shares valued at approximately $24.4 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with earnings per share of $8.38 and revenue of $22.97 billion, exceeding analyst expectations; revenue rose 47.7% year over year. The company issued fiscal 2026 EPS guidance of $35.50–$36.50.
• Analysts maintain a largely positive outlook, with a consensus “Moderate Buy” rating and a $1,292.18 price target, while insiders sold $15.96 million of stock over the past three months. Shares also carry a quarterly dividend of $1.73, yielding about 0.6%.

Meeder Advisory Services Inc. lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,367 shares of the company's stock after buying an additional 894 shares during the period. Eli Lilly and Company comprises 0.9% of Meeder Advisory Services Inc.'s holdings, making the stock its 21st largest holding. Meeder Advisory Services Inc.'s holdings in Eli Lilly and Company were worth $24,428,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LLY. Harborfront Financial Group LLC purchased a new position in Eli Lilly and Company in the second quarter worth about $353,000. Pension & Wealth Management Advisors Inc. increased its stake in Eli Lilly and Company by 4,700.0% during the second quarter. Pension & Wealth Management Advisors Inc. now owns 192 shares of the company's stock worth $231,000 after acquiring an additional 188 shares during the last quarter. Citizens Financial Group Inc. RI raised its position in Eli Lilly and Company by 1.5% during the second quarter. Citizens Financial Group Inc. RI now owns 76,092 shares of the company's stock valued at $91,266,000 after purchasing an additional 1,114 shares during the period. Tortoise Investment Management LLC lifted its stake in shares of Eli Lilly and Company by 6.7% in the 2nd quarter. Tortoise Investment Management LLC now owns 1,314 shares of the company's stock valued at $1,576,000 after purchasing an additional 82 shares during the last quarter. Finally, Banco BTG Pactual S.A. bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $248,000. Institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last three months. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,257.26 on Monday. Eli Lilly and Company has a twelve month low of $694.23 and a twelve month high of $1,292.65. The firm has a market cap of $1.18 trillion, a price-to-earnings ratio of 42.19, a PEG ratio of 1.48 and a beta of 0.51. The business's fifty day simple moving average is $1,180.14 and its two-hundred day simple moving average is $1,059.93. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business's revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's payout ratio is 23.22%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will collaborate with Boston-based Chai Discovery on an RNA vaccine platform. The partnership could expand Lilly’s technology and early-stage pipeline, though the financial impact is likely to be longer term. Lilly to work with Boston-based firm to develop RNA vaccine platform
• Positive Sentiment: Recent coverage continues to highlight Lilly’s momentum in obesity treatment, with its products reportedly outpacing Novo Nordisk’s offerings. This reinforces expectations for sustained demand and supports LLY’s growth narrative. Eli Lilly's obesity treatments outpace Novo Nordisk
• Positive Sentiment: Analyst-focused coverage identifies Eli Lilly as a leading candidate for significant earnings growth and a potential buy point as the broader market rebounds. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
• Neutral Sentiment: Lilly completed or advanced several clinical studies, including trials involving hidradenitis suppurativa, lebrikizumab, LY4178256 and eloralintide. The updates broaden the pipeline, but no decisive efficacy or regulatory results were provided. Lilly clinical-trial updates
• Neutral Sentiment: Discussion of a possible stock split reflects the sharp rise in LLY’s share price, but a split would not change the company’s fundamental value or earnings outlook. Stock Split Watch: Is Eli Lilly Stock Next?
• Negative Sentiment: Lilly continues to face competition from Novo Nordisk in the emerging oral GLP-1 market. The race creates substantial growth potential but also raises execution and market-share risks. Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race?

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. UBS Group set a $1,376.00 target price on Eli Lilly and Company in a research report on Friday, August 7th. Bank of America raised their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Jefferies Financial Group lifted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a research note on Tuesday, June 9th. Leerink Partners boosted their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a research report on Thursday, June 25th. Finally, Sanford C. Bernstein raised their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,292.18.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source